Subject: How can the inhibition of dendritic cell maturation in vitro be applied?

   Recently, the role of dendritic cells has been a focus of studies 
relating to transplant rejection and autoimmune diseases.  Maximizing the 
tolerogenic properties of these antigen presenting cells is desirable and 
may help achieve the goal of long-term allograft survival.  Many agents 
have been shown to inhibit dendritic cell maturation in vitro, resulting 
in increased tolerogenicity.  Though I have done much research (including 
on web resources such as Medline and PubMed I lack an understanding of the 
potential method of use of these agents (eg. IL-10 and TFG beta).  Would 
they be used as systemic antirejection therapy, and if so, would the body's 
ability to fight invading pathogens be limited? (I am currently in the 
research stages of a science project and considering comparing the ability 
of these different agents to inhibit dendritic cell maturation.  I would 
very much appreciate some help with this question.)  Thank you. 

Re: How can the inhibition of dendritic cell maturation in vitro be applied?